Akiko Matsusaki1, Masayuki Kaneko2, Mamoru Narukawa2. 1. Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan. matsusakiakiko_kitasato@yahoo.co.jp. 2. Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
Abstract
BACKGROUND AND OBJECTIVES: Subject dropout rates in placebo-controlled randomized clinical trials (RCTs) of antipsychotics are high. The missing values due to dropout represent a potential source of bias in clinical trials. We aimed to identify the potential factors affecting subject dropout in atypical antipsychotics RCTs by conducting a meta-analysis. METHODS: Placebo-controlled RCTs for atypical antipsychotics using positive and negative syndrome scale (PANSS) as a psychiatric assessment scale were selected by database search. The potential factors affecting subject dropout, such as publication year, study design, and operational factors, were analyzed by meta-regression. RESULTS: Forty-seven placebo controlled RCTs of atypical antipsychotics of which results were published between 1993 and 2018 were identified through the database search. In the multivariate meta-regression analysis, earlier publication year, older age of subjects, and longer study duration were significantly associated with high subject dropout rates in placebo-controlled clinical trials of atypical antipsychotics. CONCLUSION: Subject dropout rates in clinical trials of atypical antipsychotics published between 1993 and 2018 year decreased over time. Study duration should be taken into consideration when designing future studies, where short study periods yet appropriate for evaluating the efficacy of new atypical antipsychotics are preferable. Additionally, previous medications and the degree of subject satisfaction with antipsychotics might affect subject dropout rate.
BACKGROUND AND OBJECTIVES: Subject dropout rates in placebo-controlled randomized clinical trials (RCTs) of antipsychotics are high. The missing values due to dropout represent a potential source of bias in clinical trials. We aimed to identify the potential factors affecting subject dropout in atypical antipsychotics RCTs by conducting a meta-analysis. METHODS: Placebo-controlled RCTs for atypical antipsychotics using positive and negative syndrome scale (PANSS) as a psychiatric assessment scale were selected by database search. The potential factors affecting subject dropout, such as publication year, study design, and operational factors, were analyzed by meta-regression. RESULTS: Forty-seven placebo controlled RCTs of atypical antipsychotics of which results were published between 1993 and 2018 were identified through the database search. In the multivariate meta-regression analysis, earlier publication year, older age of subjects, and longer study duration were significantly associated with high subject dropout rates in placebo-controlled clinical trials of atypical antipsychotics. CONCLUSION: Subject dropout rates in clinical trials of atypical antipsychotics published between 1993 and 2018 year decreased over time. Study duration should be taken into consideration when designing future studies, where short study periods yet appropriate for evaluating the efficacy of new atypical antipsychotics are preferable. Additionally, previous medications and the degree of subject satisfaction with antipsychotics might affect subject dropout rate.
Authors: Suresh Durgam; Andrew J Cutler; Kaifeng Lu; Raffaele Migliore; Adam Ruth; István Laszlovszky; György Németh; Herbert Y Meltzer Journal: J Clin Psychiatry Date: 2015-12 Impact factor: 4.384
Authors: P Truffinet; C A Tamminga; L F Fabre; H Y Meltzer; M E Rivière; C Papillon-Downey Journal: Am J Psychiatry Date: 1999-03 Impact factor: 18.112
Authors: Antony Loebel; Josephine Cucchiaro; Kaushik Sarma; Lei Xu; Chuanchieh Hsu; Amir H Kalali; Andrei Pikalov; Steven G Potkin Journal: Schizophr Res Date: 2013-02-13 Impact factor: 4.939
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: Joseph P McEvoy; David G Daniel; William H Carson; Robert D McQuade; Ronald N Marcus Journal: J Psychiatr Res Date: 2007-07-13 Impact factor: 4.791
Authors: Andrea J Chow; Ryan Iverson; Monica Lamoureux; Kylie Tingley; Isabel Jordan; Nicole Pallone; Maureen Smith; Zobaida Al-Baldawi; Pranesh Chakraborty; Jamie Brehaut; Alicia Chan; Eyal Cohen; Sarah Dyack; Lisa Jane Gillis; Sharan Goobie; Ian D Graham; Cheryl R Greenberg; Jeremy M Grimshaw; Robin Z Hayeems; Shailly Jain-Ghai; Ann Jolly; Sara Khangura; Jennifer J MacKenzie; Nathalie Major; John J Mitchell; Stuart G Nicholls; Amy Pender; Murray Potter; Chitra Prasad; Lisa A Prosser; Andreas Schulze; Komudi Siriwardena; Rebecca Sparkes; Kathy Speechley; Sylvia Stockler; Monica Taljaard; Mari Teitelbaum; Yannis Trakadis; Clara van Karnebeek; Jagdeep S Walia; Brenda J Wilson; Kumanan Wilson; Beth K Potter Journal: BMJ Open Date: 2022-02-22 Impact factor: 2.692
Authors: Chiara Buizza; Cosmo Strozza; Giulio Sbravati; Giovanni de Girolamo; Clarissa Ferrari; Laura Iozzino; Ambra Macis; Harry G Kennedy; Valentina Candini Journal: Ann Gen Psychiatry Date: 2022-09-10 Impact factor: 3.301